Evidence map›Paper›PMID 32922002›Full record

ArticleInternational journal of nanomedicine2020

GFc7 as a Smart Growth Nanofactor for ex vivo Expansion and Cryoprotection of Humans' Hematopoietic Stem Cells.

Maryam Hafizi, Somayeh Kalanaky, Saideh Fakharzadeh, Ehsan Janzamin, Tarlan Arjmandi, Amir Atashi, Mohammad Hassan Nazaran

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maryam HafiziDepartment of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.ORCID 0000-0001-7417-6955
Somayeh KalanakyDepartment of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.ORCID 0000-0003-1797-236X
Saideh FakharzadehDepartment of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
Ehsan JanzaminFlowcyt Science-Based Company, Tehran, Iran.
Tarlan ArjmandiDepartment of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
Amir Atashi *Stem Cell and Tissue Engineering Research Center, Shahroud University of Medical Sciences, Shahroud, Iran.ORCID 0000-0002-3889-5642
Mohammad Hassan Nazaran *Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.ORCID 0000-0002-9413-2295

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNowadays, smart synthesized nanostructures have attracted wide attention in the field of stem cell nanotechnology due to their effect on different properties of stem cells.

methodsGFc7 growth nanofactor was synthesized based on nanochelating technology as an iron-containing copper chelator nanocomplex. The effect of this nanocomplex on the expansion and differentiation of hematopoietic stem cells (HSCs) as well as its performance as a cryoprotectant was evaluated in the present study.

resultsThe results showed that the absolute count of CD34

conclusionIt can be claimed that treating HSCs with GFc7 growth nanofactor leads to quality and quantity improvement of HSCs, both in terms of expansion in vitro and freezing and de-freezing processes.

Indexed as

CytoprotectionADP-ribosyl Cyclase 1Antigens, CD34Cell DifferentiationCell ProliferationCells, CulturedColony-Forming Units AssayDynamic Light ScatteringFreezingGene Expression RegulationHematopoietic Stem CellsHumansNanoparticlesReceptors, CXCR4ADP-ribosyl Cyclase 1Antigens, CD34CXCR4 protein, humanReceptors, CXCR4expansionGFc7human hematopoietic stem cellsnanochelating technologynanocomplex

Identifiers

PMID32922002
PMCPMC7457843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.